Pizzuti Dana's Form 4 filing
Crinetics Pharmaceuticals, Inc. (CRNX) · filed Jan 7, 2025
- Accession no.
- 0000950170-25-002869
- Filed
- Jan 7, 2025
- Trade date
- Jan 3-7, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $781.4K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Pizzuti DanaCIK 0001948238 | Officer (Chief Med and Dev Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2025 | Common Stock | MOption exerciseAcquired | +15,000 | $16.89 | +$253,350 | 44,248 | Direct | |
| Jan 3, 2025 | Common Stock | SSaleDisposed | −15,000 | $52.09F2 | −$781,350 | 29,248 | Direct | |
| Jan 7, 2025 | Common Stock | MOption exerciseAcquired | +2,500 | $19.64 | +$49,100 | 31,748 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2025 | Common Stock | MOption exerciseDisposed | −15,000 | $0.00 | $0 | 124,042 | Direct | |
| Jan 7, 2025 | Common Stock | MOption exerciseDisposed | −2,500 | $0.00 | $0 | 18,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $52.09 per share. The range of sales prices on the transaction date was $51.60 to $52.60 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.